DIOVAN HCT 320mg/25mg

Compare DIOVAN HCT 320mg/25mg  to:
Compare
Compare

Generic Name for DIOVAN HCT 320mg/25mg

Valsartan 320mg, hydrochlorothiazide 25mg; tabs.

Legal Classification:

Rx

Pharmacological Class for DIOVAN HCT 320mg/25mg

Angiotensin II receptor blocker + diuretic.

Manufacturer of DIOVAN HCT 320mg/25mg

Novartis Pharmaceuticals Corp

Indications for DIOVAN HCT 320mg/25mg

Hypertension.

Adult dose for DIOVAN HCT 320mg/25mg

Take once daily. Add-on or initial therapy and not volume-depleted: Initially 160mg/12.5mg; may increase after 1–2 weeks up to max 320mg/25mg. Replacement therapy: may be substituted for the titrated components. Maximum effects within 2–4 weeks after dose change. CrCl ≤30mL/min: not recommended.

Children's dosing for DIOVAN HCT 320mg/25mg

Not recommended.

Also:

Contraindications for DIOVAN HCT 320mg/25mg

Anuria. Sulfonamide allergy.

Precautions for DIOVAN HCT 320mg/25mg

Intravascular volume depletion; do not use as initial therapy. Correct salt/volume depletion before starting, or monitor closely. Hepatic or severe renal impairment. Arrhythmias. Postsympathectomy. Diabetes. Gout. Asthma. Severe CHF. Renal artery stenosis. SLE. Monitor electrolytes. Pregnancy (Cat.D; avoid in 2nd and 3rd trimesters). Nursing mothers: not recommended.

Interactions for DIOVAN HCT 320mg/25mg

Monitor for hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. Hypokalemia with corticosteroids, ACTH. Antagonized by NSAIDs, cholestyramine, colestipol resins. Orthostatic hypotension may be potentiated by alcohol, barbiturates, narcotics, antihypertensives. Potentiates nondepolarizing muscle relaxants. Antagonizes norepinephrine. Adjust antidiabetic, antigout medications. Avoid lithium. May increase toxicity of digitalis, lithium. May interfere with parathyroid tests.

Adverse Reactions for DIOVAN HCT 320mg/25mg

Headache, dizziness, nasopharyngitis, viral infection, fatigue, cough, diarrhea, orthostatic hypotension, electrolyte disturbances (eg, hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, increased serum cholesterol or triglycerides; rare: rhabdomyolysis.

How is DIOVAN HCT 320mg/25mg supplied?

Tabs—90

Related Disease:

Hypertension

Related Resources

FDA warns of reduced Plavix efficacy in poor metabolizers

March 15, 2010

The FDA has notified healthcare professionals and patients that a Boxed Warning has been added to the Plavix (clopidogrel tablets, from Bristol-Myers Squibb and Sanofi) Prescribing Information to include information about reduced Plavix efficacy in patients who are poor metabolizers of Plavix.

Benicar gains expanded indication for treatment of hypertension in children

February 11, 2010

The FDA has approved Benicar (olmesartan medoxomil tablets, from Daiichi Sankyo) for the treatment of hypertension in children and adolescents 6-16 years of age.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Cleviprex injection recalled due to presence of particulate matter

December 17, 2009

The FDA and The Medicines Company have notified healthcare professionals of a voluntary nationwide recall of 11 lots of Cleviprex (clevidipine butyrate) injection emulsion due to the presence of visible particulate matter observed in some vials.

Clonidine ER Suspension and Clonidine ER Tablets approved

December 07, 2009

Tris Pharma announced that the FDA has approved Clonidine ER suspension and Clonidine ER tablets, both of which utilize its proprietary OralXR+ platform technology to allow for once daily dosing.